膀胱癌围手术期免疫疗法

IF 58.7 1区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Nature Medicine Pub Date : 2024-10-16 DOI:10.1038/d41591-024-00074-6

引用次数: 0

摘要

在 NIAGARA 试验中，在肌肉浸润性膀胱癌标准治疗的基础上增加围手术期 durvalumab，提高了无事件生存率和总生存率，为这种疾病提供了一种新的治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Perioperative immunotherapy for bladder cancer

In the NIAGARA trial, the addition of perioperative durvalumab to standard treatment for muscle-invasive bladder cancer improved event-free and overall survival, marking a new treatment option for this condition.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Medicine 医学-生化与分子生物学

CiteScore

100.90

自引率

0.70%

发文量

525

审稿时长

1 months

期刊介绍： Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine. The publication focuses on originality, timeliness, interdisciplinary interest, and the impact on improving human health. In addition to research articles, Nature Medicine also publishes commissioned content such as News, Reviews, and Perspectives. This content aims to provide context for the latest advances in translational and clinical research, reaching a wide audience of M.D. and Ph.D. readers. All editorial decisions for the journal are made by a team of full-time professional editors. Nature Medicine consider all types of clinical research, including: -Case-reports and small case series -Clinical trials, whether phase 1, 2, 3 or 4 -Observational studies -Meta-analyses -Biomarker studies -Public and global health studies Nature Medicine is also committed to facilitating communication between translational and clinical researchers. As such, we consider “hybrid” studies with preclinical and translational findings reported alongside data from clinical studies.